MIRLET7E: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

Target Name: MIRLET7E

NCBI ID: G406887

MIRLET7E

MIRLET7E: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

MIRLET7E (hsa-let-7e-5p) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed light on its role in various biological processes.

MIRLET7E is a short non-coding RNA molecule that consists of 52 amino acid residues. It is expressed in a variety of tissues and cells in the body and is involved in various cellular processes, including cell growth, differentiation, and RNA translation. One of its unique features is its ability to interact with other non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncNs), to regulate their stability and function.

MIRLET7E has been shown to play a role in the regulation of gene expression in various organisms, including humans. For example, studies have shown that MIRLET7E can interact with miRNAs that are involved in cell proliferation and have anti-proliferative effects. Additionally, MIRLET7E has been shown to regulate the translation efficiency ofmiRNAs in cancer cells, which may contribute to their uncontrolled growth.

MIRLET7E has also been shown to be involved in the regulation of cellular processes that are important for maintaining brain health, including the regulation of neurotransmitter synthesis and the modulation of synaptic plasticity. Studies have shown that MIRLET7E can interact with neurotransmitter synthases and modulate their activity, which may be involved in the regulation of mood, anxiety, and learning processes.

In addition to its role in cellular processes, MIRLET7E has also been shown to play a role in the regulation of stem cell properties. Studies have shown that MIRLET7E can interact with stem cell markers, including the CD133 protein, and have pro-stimulatory effects on stem cell proliferation. This may be important for understanding the mechanisms of stem cell therapy and the development of cancer therapies.

MIRLET7E has also been shown to be involved in the regulation of immune responses and has been implicated in the development of autoimmune disorders. Studies have shown that MIRLET7E can interact with immune cell markers, including T cells and B cells, and have anti-inflammatory effects. This may be important for understanding the mechanisms of autoimmune diseases and the development of new therapies.

In conclusion, MIRLET7E is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for several diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed light on its role in various biological processes. Further research is needed to fully understand the mechanisms of MIRLET7E's role in disease and to develop new therapies that target this promising molecule.

Protein Name: MicroRNA Let-7e

The "MIRLET7E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIRLET7E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets